Diabetes and cardiovascular disease: The potential benefit of incretin-based therapies

Daniel Addison, David Aguilar

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


The health burden of type 2 diabetes mellitus continues to increase worldwide. A substantial portion of this burden is due to the development of cardiovascular disease in patients with diabetes. Recent failures of clinical trials of intensive glucose control to reduce macrovascular events, coupled with reports of potential harm of certain diabetic therapy, have led to increased scrutiny as new diabetic therapies are developed. Incretin peptides are a group of gastrointestinal proteins that regulate glucose metabolism through multiple mechanisms, and incretin-based therapies have been developed to treat type 2 diabetes. These agents include glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-IV (DPP-IV) inhibitors. In addition to effects on glucose homeostasis, growing evidence suggest that these peptides may also affect the cardiovascular system. In this review, we discuss recent findings concerning the potential, yet untested, benefits of incretin-based pharmacotherapy in the treatment of cardiovascular disease.

Original languageEnglish
Pages (from-to)115-122
Number of pages8
JournalCurrent Atherosclerosis Reports
Issue number2
StatePublished - Apr 2011


  • DPP-IV
  • Diabetes
  • Glucagon-like peptide 1
  • Incretin hormones cardiovascular disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Diabetes and cardiovascular disease: The potential benefit of incretin-based therapies'. Together they form a unique fingerprint.

Cite this